Over five years, researchers estimate more than $9 million in insurance savings
FRIDAY, March 18, 2016 (HealthDay News) — Using the generic version of the cancer drug Gleevec could save patients and insurers millions of dollars, according to a study published online March 4 in the Journal of the National Cancer Institute.
The patent on Gleevec expired in January. The generic version of the drug is imatinib.
The researchers calculated that if all chronic myeloid leukemia patients began receiving imatinib immediately after diagnosis, the cost of treatment per patient over five years would be nearly $100,000 less than with Gleevec. They also concluded that the use of imatinib instead of Gleevec would save a health insurer with 100 chronic myeloid leukemia patients more than $9 million over five years.
“If we start all patients on the generic form of Gleevec and it works, then they are on a generic for the rest of their lives,” study leader William Padula, Ph.D., an assistant professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore, said in a school news release. “This amounts to a huge cost savings for them and their insurers.”
Several authors disclosed financial ties to pharmaceutical companies with a vested interest in the chronic myeloid leukemia market.
Childhood Cancer Survivors Often Have Mental Distress in Adulthood 
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
2021 to 2026 Saw Increase in State Funding for Suicide Prevention 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
